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Abstract
Background: Bronchial epithelium is a target of the alloimmune response in lung transplantation, and intact
epithelium may protect allografts from rejection and obliterative bronchiolitis (OB). Herein we study the influence
of chimerism on bronchial epithelium and OB development in pigs.
Methods: A total of 54 immunosuppressed and unimmunosuppressed bronchial allografts were serially obtained
2-90 days after transplantation. Histology (H&E) was assessed and the fluorescence in situ hybridization (FISH)
method for Y chromosomes using pig-specific DNA-label was used to detect recipient derived cells in graft
epithelium and bronchial wall, and donor cell migration to recipient organs. Ingraft chimerism was studied by
using male recipients with female donors, whereas donor cell migration to recipient organs was studied using
female recipients with male donors.
Results: Early appearance of recipient-derived cells in the airway epithelium appeared predictive of epithelial
destruction (R = 0.610 - 0.671 and p < 0.05) and of obliteration of the bronchial lumen (R = 0.698 and p < 0.01). All
allografts with preserved epithelium showed epithelial chimerism throughout the follow-up. Antirejection medication
did not prevent, but delayed the appearance of Y chromosome positive cells in the epithelium (p < 0.05), or
bronchial wall (p < 0.05).
Conclusions: In this study we demonstrate that early appearance of Y chromosomes in the airway epithelium
predicts features characteristic of OB. Chimerism occurred in all allografts, including those without features of OB.
Therefore we suggest that ingraft chimerism may be a mechanism involved in the repair of alloimmune-mediated
tissue injury after transplantation.
Background
The migration of recipient-derived cells into grafted
organs has been demonstrated in heart, liver, and kidney
transplants [1-3]. It has been postulated, that these chi-
meric recipient-derived epithelial and endothelial cells
may participate in the graft repair process in lung and
liver allografts [2,4]. In lung allografts the bronchial epithe-
lium seems to be a target of the alloimmune response and
an intact epithelium is capable of protecting the allografts
from chronic rejection i.e. obliterative bronchiolitis (OB).
Therefore the integrity of airway epithelium is important
for graft preservation [5,6]. Histologically OB is manifested
as epithelial cell injury, inflammation, fibrosis, and finally,
as obliteration of the small airways [7]. Clinically it is the
most important factor limiting long-term survival after
lung transplantation [7]. The development of chimerism
may also be influenced by antirejection medication [8,9].
After transplantation, donor-derived cells have been
detected in the recipient’s other tissues, such as lymph
nodes, thymus, spleen, and liver [10,11]. The exact role
of chimeric cells in transplantation is unclear, but pre-
vious studies have proposed that the migration of donor-
derived cells into recipient tissues induces tolerance in
the recipient [12,13]. To further enhance such systemic
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In previous studies mixed chimerism has been suggested
to increase tolerance in kidney, liver, heart, and lung
transplantation [14-18]. In clinical lung transplantation,
infusion of donor bone marrow lowered the rate of
chronic lung allograft rejection [19]. As the adverse
effects of immunosuppressive treatment may also limit
the outcome of transplantation, the induction of specific
immunological tolerance in the recipient remains an
important objective in transplantation.
In this study our goal was to analyse, whether the
repaired epithelium in the allograft is recipient-derived,
and whether ingraft chimerism in bronchial allografts
protects transplants from rejection in a heterotopic por-
cine model of OB [20]. We also analysed the migration
of graft-derived cells into recipient organs.
Methods
All animals received humane care in compliance with the
“Principles of Laboratory Animal Care” formulated by
the National Society for Medical Research and the
“Guide for the Care and Use of Laboratory Animals” pre-
pared by the Institute of Laboratory Animal Resources
and published by the National Institutes of Health (NIH
Publication No. 86-23, revised 1996). The study protocol
was accepted by the institutional committee for animal
research and by the Uusimaa Provincial Administration,
Finland (STU828 A). Special attention was given to
anesthesia and pain relief during surgical procedures.
Animals were euthanized at the end of the study.
Medication, anesthesia, and surgical procedures
We used 27 random-bred, domestic pigs weighing ca.
20 kg. Animals were anesthetized for the surgical proce-
dures as previously described [21]. Left thoracotomy was
performed for removal of the caudal lobe. Peripheral bron-
chial segments (1-2 cm in length and 1-2 mm in diameter)
were dissected free of the surrounding lung parenchyma.
These implants were transplanted subcutaneously on the
ventral side of each recipient, several implants in all to be
removed on each assessment point.
Study design
To study chimerism in bronchial allografts female ani-
mals served as allograft donors while the recipients were
male. A male autograft served as a control for the fluor-
escence in situ hybridization (FISH) method. Allografts
without immunosuppressive medication were expected
to exhibit rapid destruction of the airway epithelium and
obliteration of the lumens of the bronchial allografts. The
grafts were followed up to one month. To achieve
delayed bronchial obliteration daily oral cyclosporine A
10 mg/kg, methylprednisolone 20 mg, and azathioprine
50 mg were given, and the grafts were followed up to one
month. In order to prevent bronchial obliteration recipi-
ents received an immunosuppressive regimen of daily
oral cyclosporine A 10 mg/kg, methylprednisolone
20 mg, and everolimus 1.5 mg/kg. The total follow-up
time of these grafts was three months. At the end of the
study, animals were euthanized with a high intravenous
dose of sodium pentobarbital.
Bronchial allografts were harvested in the non-treated
and inadequately treated groups on days 2, 4, 7, 10, 14,
and 28. In the adequately treated group follow-up was
extended to days 60 and 90. A total of 54 bronchial sam-
ples were fixed in 4% buffered formalin and embedded in
wax. Sections 4 μm thick were cut, dewaxed, and stained
with hematoxylin and eosin. Epithelial loss and luminal
obliteration were graded semi-quantitatively on a scale
from 0 (no pathological alteration) to 3 (total epithelial
loss, total obliteration).
To further assess chimerism and tolerance induction
we studied the migration of donor cells into recipient
organs: lung, liver, kidney, and spleen. Five female recipi-
ents with male donors were either non-treated, or treated
adequately with daily oral cyclosporine A 10 mg/kg,
methylprednisolone 20 mg, and everolimus 1.5 mg/kg. In
addition, two male recipients with female donors were
studied as controls. One was non-treated, and the other
one was adequately treated. After a follow-up period of
three months, a total of 28 samples were harvested from
recipient lung, liver, kidney, and spleen, and prepared
similarly to bronchial samples.
FISH method to detect Y chromosome
The FISH method was used to detect Y chromosomes.
Paraffin embedded tissue sections were baked at 56°C for
2-6 h. Deparaffinization was accomplished by immersing
the slides in xylene for 3 × 7 min followed by dehydration
in ethanol for 2 × 5 min and air drying. Then the slides
were sequentially incubated in 0.2 M HCl at room tem-
perature for 25 min, 10 mM citric acid at 80°C for 60 min,
8% sodium thiocyanate at room temperature overnight
and 0.025 pepsin/0.01 M HCl at 38°C for 55 min. Each
incubation step was followed by washing in 2 × SSC for
2 × 5 min. Finally, the slides were fixed in 4% paraformal-
dehyde for 11 min, washed in 2 × SSC, dehydrated in etha-
nol series and air dried. Whole chromosome painting
probe specific for pig Y chromosome was prepared by
laser microdissection [22]. Satellite probe for centromeric
region of chromosome 1, used as hybridization control,
was prepared on the basis of Mc1 satellite DNA sequence
data (X51555) as described by Rubes et al. [23]. Hybridiza-
tion mixture (10 μl) containing 50% formamide, 2 × SSC,
10% dextran sulfate, 5 μgs a l m o ns p e r mD N A ,5 0n go f
labelled Y chromosome probe and 30 ng labelled chromo-
some 1 probe was denatured at 80°C for 10 min. Slides
were denatured in 70% formamide, 2 × SSC (pH 7.0) at
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night at 37°C. Slides were washed twice in 0.4 × SSC/0.3%
igepal (pH 7) at 72°C for 2 min. Fluorescent signals from
male recipient epithelium, bronchial wall, and female reci-
pient organs; lung, liver, kidney and spleen, were scored
using fluorescent microscopy with magnification 1000×
(objective 100× lens and ocular 10×). Findings were
graded on a semi-quantitative scale from 0 to 3 based on
the number of positive cells (0 = no positive cells, 1 = less
than 20% of cells stain positive, 2 = 20% - 50% of cells are
positive, 3 = more than 50% cells stain positive).
Statistics
All data are expressed as mean + SEM. Variations
between the groups were calculated by the non-para-
metric Kruskal-Wallis one-way analysis by ranks. The
rank sums were then used for Dunn’s test at significance
level of 5% (Medstat; Astra Group A/S, Copenhagen,
Denmark). Values of p <0 . 0 5w e r ec o n s i d e r e ds i g n i f i -
cant. For correlation analysis, Spearman’s rank correla-
tion (Statistica version 5; StatSoft Inc., Tulsa, OK) was
used.
Results
Epithelial loss and obliteration
After initial ischemic injury, the respiratory epithelium
of allografts with no immunosuppression first showed a
tendency to restore. Epithelial loss was subtotal on day
7, and was followed by gradual obliteration of the bron-
chial lumen (Figures 1A and 1B). In the beginning of
the follow-up, the inadequately treated allografts showed
less extensive epithelial destruction (Figure 2A), the dif-
ference in epithelial loss between the inadequately trea-
ted group and non-treated group was significant on
follow-up days 4, 7, and 10 (p <0 . 0 5 ) .H o w e v e r ,b yd a y
30 the lumens of the inadequately treated allografts also
occluded totally (Figures 1A and 1B). In the adequately
treated group (Figure 2B) and in a control autograft
(Figure 2C), only mild epithelial destruction occurred.
The difference in epithelial loss between the adequately
treated allografts and non-treated allografts was signifi-
cant from day 7 on (p < 0.05). The difference in epithe-
lial loss between the adequately treated allografts and
the inadequately treated allografts was significant from
day 10 on (p < 0.05). No obliterative lesions of the bron-
chial lumens were observed in adequately treated allo-
grafts (Figure 1B). Luminal obliteration of adequately
treated allografts differed significantly from non-treated
allografts on days 10 and 30 (p < 0.05), and from inade-
quately treated allografts on days 14 and 30 (p < 0.05).
Chimerism
All samples stained positive for chromosome 1 (Figures
2D, E, and 2F) and the control male autograft stained
positive for the Y chromosome indicating successful hybri-
dization (Figure 2F). Positive staining for the Y chromo-
some in bronchial allografts from female donors indicated
the presence of recipient-derived cells. Cells showing posi-
tive staining for the Y chromosome were observed in all
groups both in the respiratory epithelium and in the bron-
chial wall (Figures 1C and 1D).
Since the respiratory epithelium in the non-treated
allografts underwent rapid destruction, epithelial Y chro-
mosomes were observed only at the first assessment
points (Figure 1C). In the adequately treated allografts,
the number of Y chromosome positive cells in the
epithelium increased until day 10 (Figures 1C and 2E).
In the respiratory epithelium, Y chromosome positive
cells were significantly more numerous on days 10, 14,
a n d2 8t h a no nf o l l o w - u pd a y4( p < 0.05). Positive
staining for the Y chromosome was observed in the pre-
served epithelium during the entire follow-up, up to
three months (Figure 1C). Antirejection medication did
not prevent, but delayed positive staining for the Y
chromosome in the epithelium (p< 0.05 on day 4)
(Figure 1C). Early appearance of Y chromosome positive
cells in the airway epithelium appeared predictive of
epithelial destruction and obliteration of the bronchial
lumen (Table 1).
Positive staining for the Y chromosome was more
numerous in the bronchial wall than in the epithelium
on days 4 (p = 0.001) and 7 (p < 0.0001) and from day
14 onwards until the end of the follow-up (p < 0.01)
(Figures 1C and 1D). In the bronchial wall, Y chromo-
some staining was significantly more frequent on fol-
low-up day 14 and thereafter than on day 4 (p < 0.05).
As in the epithelium, antirejection medication delayed
positive staining for the Y chromosome in the bronchial
wall (p < 0.05, day 4 and 10).
Histologic assessment of the recipient organ samples
(lung, liver, kidney and spleen) collected for evaluation
of chimerism showed normal histology without adverse
effects of medication. The male recipient organs served
as controls for the FISH method, and they stained posi-
tive for Y chromosomes, whereas organ samples (lung,
liver, kidney, and spleen) in female recipients with male
bronchial allograft donors were negative. Thus, no
donor-derived cells were observed in the recipient organ
samples.
Discussion
In this study we assessed the presence of chimeric cells in
bronchial transplants and their relationship to graft rejec-
tion. We demonstrated that early appearance of recipient-
derived cells in the airway epithelium is predictive of
epithelial destruction and obliteration of the bronchial
lumen. The non-treated allografts underwent rapid epithe-
lial destruction followed by total luminal obliteration while
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slightly delayed in inadequately treated allografts. As
expected, bronchial remodelling was prevented in the ade-
quately treated allografts [21], which showed only low-
grade epithelial destruction after recovery from the initial
ischemic injury. We have previously shown that the
advanced epithelial injury occurring in the non-treated or
inadequately treated allografts is an alloimmune response
with CD4, CD8, and class II positive cell influx [24]. This
response results in airway disease with similar histological
findings as in human post-transplant OB.
Epithelial chimerism occurred in all groups through-
out the follow-up. In the recovering allografts the num-
ber of Y chromosome positive cells increased in parallel
with the recovery of the respiratory epithelium. Early
appearance of recipient-deriv e dc e l l s ,h o w e v e r ,c o r r e -
lated with further epithelial cell injury and obliteration.
It has been shown that epithelial chimerism after trans-
plantation is increased by cellular damage with elevated
cell turn over [4,25]. Our finding of low-grade chimer-
ism also in the recovered epithelium of the adequately
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Figure 1 Destruction of airway epithelium (A) and obliteration of the bronchial lumen (B), and the positive staining for Y
chromosomes in the epithelium (C) and in the bronchial wall (D). The study groups were non-immunosuppressed, inadequately
immunosuppressed, or adequately immunosuppressed. Epithelial destruction, luminal obliteration, and positive staining for Y chromosomes were
graded on a scale from 0-3. The number of assessed bronchi in each group and on each assessment point was 6.6. ± 1.1 for histological
samples and 7.1. ± 1.1 for FISH.
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Figure 2 Table 2. Histological alterations (A,B,C) and chimerism (D,E,F) in bronchial allografts (A,B,D,E) and in a control autograft (C,F).
Epithelial damage is observed in a bronchial allograft on follow-up day 4 (A) and recovered epithelium and bronchial wall structure on day 7 in
an adequately treated allograft (B). H&E, original magnification ×10. Recovery of the adequately treated allograft (B) was similar to that of a
control autograft (C) on day 7. H&E, original magnification ×10. Tissue section of a bronchial allograft of female origin in a male recipient
hybridized with probes for pig chromosomes Y (red) and 1 (green) on day 7 (D) shows epithelial and bronchial wall cells with Y chromosomes.
Y chromosomes are more frequent on follow-up day 10 (E) than on follow-up day 7 (D) in recovered epithelium in adequately treated allografts.
Chromosomes Y (red) and 1 (green) stain invariably (F) in a male control autograft on follow-up day 7 and confirm successful hybridization.
Staining with 4’,6-diamidino-2-phenylindole, original magnification ×1000.
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The adult human lung has a capacity to renew itself by
extrapulmonary cells [26] and it has been demonstrated
that re-epithelisation with recipient-derived epithelium
protects allografts from immune-mediated injury and
results in allograft tolerance [27].This was seen also in
the present study. The very rapid initiation of chimeric
cell migration into the rejected allografts might be an
insufficient attempt to protect the epithelium against
the alloimmune reaction. The chimeric cells might origi-
nate from recipient bone-marrow or hematopoietic stem
cells, which are capable of engrafting into the bronchial
epithelium of the graft as a part of the repair process
[28-30]. On the contrary, whilst the early migration of
chimeric cells correlated with subsequent OB, it might
be a sign of an active role in this cascade.
An alloimmune injury of the respiratory epithelium is
known to result in the secretion of profibrotic factors,
which contribute to the development of OB [31]. Mura-
kawa et al found a correlation between the extent of
epithelial chimerism and airway remodelling [25]. They
also showed that chimeric epithelium prevented luminal
fibrosis [25]. In the current study, bronchial wall chimerism
occurred in all groups, including allografts without findings
of bronchial remodelling. As in the epithelium, medication
delayed its occurrence. Recipient-derived myofibroblasts
have been suggested to participate in fibrogenesis of the
human lung [32]. In addition, chimeric endothelial cells
have been detected at sites of endothelial injury [1]. It is
unclear, whether recipient-derived endothelial cells are
associated with repair or rejection of the graft [1]. The role
of bronchial wall chimerism remains unresolved. Similarly
to epithelial chimerism, it was present in patent allografts
throughout the study and might, thus, be a protection
mechanism of the transplanted graft.
Migration of donor-derived cells to recipient tissues
after transplantation has been suggested as a mechanism
for the initiation and maintenance of tolerance in trans-
plantation. Based on this, donor derived cells would be
expected to be present in tissue samples of adequately
medicated recipients with preserved allografts [33,34]. In
our study, adequately medicated animals did show toler-
ance against allografts, but we could not detect donor-
derived cells in recipient organs, not even after three
months follow-up. This finding suggests that tolerance
in our model was achieved by immunosuppressive regi-
men and potential impact of ingraft chimerism, but
migration of donor-derived cells into recipient organs
did not play a role.
As a limitation of our model and in contrast with clini-
cal lung transplantation, the grafts in our model of OB
undergo initial avascularity prior to neovascularisation,
and there is a lack of air-epithelial interface. However,
the appearance of blood supply is rapid [20]. Animal
models are suitable for studies of mechanisms of post-
transplant airway disease. However, clinical studies can
not be replaced.
Conclusions
This study shows that early appearance of recipient-
derived cells in the airway epithelium is predictive of fea-
tures observed in post-transplant OB. However, ingraft
chimerism might be an attempt to repair tissue damaged
as a consequence of the alloimmune response after allo-
graft transplantation. Therefore, methods reinforcing
ingraft chimerism might be beneficial after lung
transplantation.
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Table 1 Correlations between Y chromosome positivity
and features of OB
Y CHROMOSOMES IN BRONCHIAL
EPITHELIUM
day 4 (N = 21) day 7 (N = 18)
R/p R/p
EPITHELIAL LOSS
day 10 (N = 21) 0.646/0.004
day 14 (N = 18) 0.618/0.011
day 30 (N = 17) 0.610/0.016
LUMINAL OBLITERATION
day 14 (N = 18) 0.671/0.024 0.698/0.005
Correlations between epithelial Y chromosome positivity (FISH-method) on
follow-up days 4 and 7 and the epithelial loss and luminal obliteration. The
bronchial allografts are from female donors and the recipients are male. (N)
gives the number of bronchi studied on the assessment points.
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